期刊
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
卷 149, 期 8, 页码 5397-5404出版社
SPRINGER
DOI: 10.1007/s00432-022-04491-3
关键词
Brachytherapy; Prostate cancer; Focal therapy; Biochemical failure; MRI
类别
This study evaluated the oncologic, functional, and toxicological results of mid-term F-BT therapy in patients with low to intermediate-risk prostate cancer. The results showed that F-BT is a safe and effective treatment for selected patients.
Purpose A potential method for focal therapy in locally advanced prostate cancer is focal brachytherapy (F-BT). The purpose of this research was to evaluate midterm F-BT oncologic, functional, and toxicological results in men who had therapy for prostate cancer. Materials and methods Between 2016 and 2020, F-BT was used to treat 37 patients with low- to intermediate-risk prostate cancer. The recommended dosage was 20 Gy. Failure was defined as the existence of any prostate cancer that has persisted in-field after treatment. The F-BT oncologic and functional outcomes served as the main and secondary objectives, respectively. Results A median 20-month follow-up (range 14-48 months). 37 patients received F-BT and enrolled in the study; no patient experienced a biochemical recurrence in the first 24 months, according to Phoenix criteria. In the control biopsies, only 6 patients showed in-field failure. The median initial IPSS was 6.5, at 6 months was 6.0, and at 24 months was 5.0. When the median ICIQ-SF score was 0 at the baseline, it remained 0 at 6-, 12-, and 24 months. Overall survival and biochemical disease-free survival after 3 years were all at 100% and 86.4%, respectively. There was no notable acute gastro-intestinal (GI) or genitourinary (GU) adverse effects. No intraoperative or perioperative complications occurred. Conclusions For selected patients with low- or intermediate-risk localized prostate cancer, F-BT is a safe and effective therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据